NAPLES,
FLA, May 24, 2022 /PRNewswire/ - Enveric
Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the
"Company"), a neuroscience-focused biotechnology company developing
next-generation, psychedelic-inspired mental health medicines,
today announced that Avani
Kanubaddi, President and Chief Operating Officer of Enveric,
will participate virtually in Microdose's Psychedelic Capital:
May 2022 Conference to be held
virtually on May 26, 2022.
Mr. Kanubaddi will participate on a panel "The Spinoffs -
Divide and Conquer" on Thursday, May
26th at 4:05 p.m.
ET. The panel will discuss the latest spinoffs among
publicly traded companies to stay competitive, honor the
shareholders and combat the markets. Register to attend here.
For more information about the conference, or to schedule a
one-on-one meeting with Enveric's management team, please send an
email to KCSA Strategic Communications
at EnvericBio@kcsa.com.
About Enveric Biosciences
Enveric Biosciences, Inc.
(NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company
developing next-generation, psychedelic-inspired mental health
medicines. Enveric's robust pipeline supports drug development from
the clinic to commercialization aimed to help millions of patients
in need around the world suffering from conditions that include
cancer-related distress, PTSD and more. For additional information,
please visit www.enveric.com.
Forward-Looking Statements
This press release contains
forward-looking statements and forward-looking information within
the meaning of applicable securities laws. These statements relate
to future events or future performance. All statements other than
statements of historical fact may be forward-looking statements or
information. Generally, forward-looking statements and information
may be identified by the use of forward-looking terminology such as
"plans,"" expects" or "does not expect," "proposed," "is expected,"
"budgets," "scheduled," "estimates," "forecasts," "intends,"
"anticipates" or "does not anticipate," or "believes," or
variations of such words and phrases, or by the use of words or
phrases which state that certain actions, events or results may,
could, would, or might occur or be achieved. Forward-looking
statements consist of not purely historical statements, including
any statements regarding beliefs, plans, expectations, or
intentions regarding the future. Such forward-looking statements
are based on the beliefs of management as well as assumptions made
by and information currently available to management. Actual
results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors,
including, but not limited to, the ability of the company to
successfully spin-off its cannabinoid assets; the ability to
achieve the value creation contemplated by technical developments;
the impact of the novel coronavirus (COVID-19) on Enveric's ongoing
and planned clinical trials; the geographic, social and economic
impact of COVID-19 on Enveric's ability to conduct its business and
raise capital in the future when needed; delays in planned clinical
trials; the ability to establish that potential products are
efficacious or safe in preclinical or clinical trials; the ability
to establish or maintain collaborations on the development of
therapeutic candidates; the ability to obtain appropriate or
necessary governmental approvals to market potential products; the
ability to obtain future funding for developmental products and
working capital and to obtain such funding on commercially
reasonable terms; Enveric's ability to manufacture product
candidates on a commercial scale or in collaborations with third
parties; changes in the size and nature of competitors; the ability
to retain key executives and scientists; and the ability to secure
and enforce legal rights related to Enveric's products, including
patent protection. A discussion of these and other factors,
including risks and uncertainties with respect to Enveric, is set
forth in Enveric's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any
intention or obligation to revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-the-microdose-psychedelic-capital-conference-on-may-26-2022-301554308.html
SOURCE Enveric Biosciences